- Home
- TLRY vs ZLAB Comparison
TLRY vs ZLAB Comparison
Compare TLRY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | ZLAB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TLRY | ZLAB |
|---|---|---|
| Price | $11.41 | $17.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $150.00 | $57.22 |
| AVG Volume (30 Days) | ★ 9.5M | 827.4K |
| Earning Date | 01-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,766,000.00 | $441,629,000.00 |
| Revenue This Year | $7.28 | $30.20 |
| Revenue Next Year | $4.51 | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.31 | ★ 24.14 |
| 52 Week Low | $3.51 | $17.72 |
| 52 Week High | $23.20 | $44.34 |
Technical Indicators
Market Signals| Indicator | TLRY | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 86.25 | 17.41 |
| Support Level | $7.10 | $19.40 |
| Resistance Level | $8.64 | $18.67 |
| Average True Range (ATR) | 0.73 | 0.51 |
| MACD | 0.78 | 0.07 |
| Stochastic Oscillator | 90.74 | 1.85 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.